AstraZeneca announced that its experimental drug "Ansilimimab" did not achieve the primary goal during an advanced clinical study targeting a rare disease known as light chain amyloidosis, which causes harmful protein deposits within the body's organs such as the heart and kidneys.
This announcement caused AstraZeneca's shares to drop by more than 1% during trading on Wednesday, amid disappointment among investors regarding the drug's feasibility in its current phase.
The study conducted by AstraZeneca aimed to evaluate the effectiveness of "Ansilimimab" in reducing hospital admissions due to cardiovascular complications, as well as reducing the overall mortality rate compared to a placebo.
Although statistically significant results were not achieved across all participants, AstraZeneca indicated that the drug showed clinically meaningful improvement in a subset of patients, without disclosing details about that group.
Some analysts believe that the overall failure of the drug in the study may be considered a negative development; however, hope remains as AstraZeneca seeks regulatory approval in the future, especially if it provides detailed results regarding the subset that responded to the treatment.
All patients participating in AstraZeneca's study received standard treatments for plasma cell disorders, in addition to "Ansilimimab" or a placebo. The company points out that this drug is the first of its kind to show clinical signs of benefit in light chain amyloidosis.
On the trading front, AstraZeneca's stock (LON: AZN) recorded a decline of 1.07%, trading near levels of 10,384.00 British pounds during London Stock Exchange transactions.
